menu
    • menu
    [{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Chinook Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Chinook Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Private Placement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Chinook Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ SVB Leerink"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Komodo Health","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Komodo Health","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Komodo Health"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.11,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":3.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":3.5,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":3.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":3.5,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"SanReno Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"SanReno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SanReno Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"SanReno Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Atrasentan

    Menu

    Atrasentan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    AbbVie Inc

    U.S.A
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase III

    Sponsor : Chinook Therapeutics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatmen...

    Details : Chinook Therapeutics in-license of atrasentan provides a unique opportunity for Chinook to add a potential new drug to its precision medicine portfolio for the treatment of rare CKD conditions.

    Product Name : CHK-01

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    January 10, 2020

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Sponsor : Chinook Therapeutics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    Abbvie Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Novartis Pharmaceuticals Corporation

    Switzerland arrow
    Conjugates Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Novartis Shows Proteinuria Reduction Data from Atrasentan Phase III Trial in IgAN

    Details : CHK-01 (atrasentan HCl) is an investigational oral endothelin A receptor antagonist (ERA), currently in Phase III development for IgAN and early-stage development for other rare kidney diseases

    Product Name : CHK-01

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 25, 2024

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    SanReno Therapeutics

    China arrow
    Conjugates Summit
    Not Confirmed

    SanReno Therapeutics

    China arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase III

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    SanReno Acquired By Novartis for Kidney Disease Therapeutics

    Details : Novartis will acquire SanReno's pipeline, gaining exclusive rights for Greater China and Singapore for late-stage IgAN assets, ABT-627 (oral ERA antagonist) and zigakibart (monoclonal antibody).

    Product Name : ABT-627

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    January 05, 2024

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Novartis Pharmaceuticals Corporation

    Switzerland arrow
    Conjugates Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statisticall...

    Details : CHK-01 (atrasentan hydrochloride) is an investigational oral endothelin A receptor antagonist (ERA), currently in Phase III development for IgAN and early-stage development for other rare kidney diseases

    Product Name : CHK-01

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 30, 2023

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Novartis Pharmaceuticals Corporation

    Switzerland arrow
    Conjugates Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Novartis Investigational Atrasentan Phase III Study Demonstrates Clinically Meaningful and Highly Statisticall...

    Details : CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist is being evaluated phase 3 clinical trials for proteinuria reduction in patients with IgA nephropathy.

    Product Name : CHK-01

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 30, 2023

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase III

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : $3,500.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Novartis Completes Acquisition of Chinook Therapeutics

    Details : Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunogl...

    Product Name : CHK-01

    Product Type : Small molecule

    Upfront Cash : $3,500.0 million

    August 11, 2023

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : $3,500.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase III

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : $3,500.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Novartis Bolsters Innovative Medicines Strategy and Renal Pipeline with Agreement to Acquire Chinook Therapeut...

    Details : Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunogl...

    Product Name : CHK-01

    Product Type : Small molecule

    Upfront Cash : $3,500.0 million

    June 12, 2023

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : $3,500.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Coh...

    Details : Atrasentan (CHK-01), is a potent and selective endothelin A receptor antagonist that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserv...

    Product Name : CHK-01

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    November 03, 2022

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase III

    Sponsor : SVB Securities

    Deal Size : $105.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Chinook Therapeutics Announces Pricing of a $105 Million Public Offering

    Details : Chinook intends to use the net proceeds from this offering to continue its phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, fund a phase 3 clinical trial of BION-1301, continue development of CHK-336 and prepare for the potential commercial launc...

    Product Name : CHK-01

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    May 25, 2022

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Sponsor : SVB Securities

    Deal Size : $105.0 million

    Deal Type : Public Offering

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    Chinook Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and ...

    Details : CHK-01 (atrasentan) is a potent and selective inhibitor of the endothelin A receptor that has potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preser...

    Product Name : CHK-01

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 20, 2022

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth